⌘K
Loading ticker…
As of 2026-08-24, Royalty Pharma plc Class A Ordinary Shares (RPRX) has a 3-month relative strength percentile of 71 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 61. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.4%, relative volume 0.83×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
RPRX is in a stage 2 uptrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 6.7% / 27.2%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
RPRX is held by 34 ETFs as of May 2026. Top owner: OUSM at 3.07% weight, $27M notional. Top 3 carry $63M.
Held by 65 ETFs · $799M across latest filings · largest weight 4.70% (IHE).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| OUSM | 3.07% | $27M | +0.55 pp |
| ESGU | 0.11% | $19M | — |
| PABU | 0.65% | $17M | +0.04 pp |
| AUSF | 1.67% | $14M | −0.54 pp |
| VONVVanguard Russell 1000 Value ETF | 0.06% | $14M | — |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 1.11% |
| $12M |
| +0.13 pp |
| VFMV | 1.29% | $6M | +0.08 pp |
| ESGV | 0.04% | $5M | — |
| AVUSAvantis U.S. Equity ETF | 0.03% | $5M | — |
| PBUS | 0.03% | $4M | — |
Showing 10 of 34 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RPRX Jan avg: 7.97% median: 4.47% win: 75% σ: 11.19% n: 4 2022-04-12 → 2026-07-31 | RPRX Feb avg: 3.93% median: 6.70% win: 75% σ: 8.54% n: 4 2022-04-12 → 2026-07-31 | RPRX Mar avg: -0.76% median: 0.30% win: 75% σ: 4.76% n: 4 2022-04-12 → 2026-07-31 | RPRX Apr avg: 0.24% median: 2.60% win: 60% σ: 5.89% n: 5 2022-04-12 → 2026-07-31 | RPRX May avg: 0.04% median: -1.05% win: 40% σ: 6.85% n: 5 2022-04-12 → 2026-07-31 | RPRX Jun avg: 0.48% median: 0.56% win: 60% σ: 6.07% n: 5 2022-04-12 → 2026-07-31 | RPRX Jul avg: 3.74% median: 3.45% win: 100% σ: 1.95% n: 5 2022-04-12 → 2026-07-31 | RPRX Aug avg: -2.00% median: -3.05% win: 25% σ: 3.55% n: 4 2022-04-12 → 2026-07-31 (current) | RPRX Sep avg: -4.35% median: -3.22% win: 0% σ: 3.20% n: 4 2022-04-12 → 2026-07-31 | RPRX Oct avg: 1.54% median: 2.17% win: 50% σ: 5.22% n: 4 2022-04-12 → 2026-07-31 | RPRX Nov avg: 2.50% median: 2.32% win: 75% σ: 3.47% n: 4 2022-04-12 → 2026-07-31 | RPRX Dec avg: -3.53% median: -3.88% win: 25% σ: 5.70% n: 4 2022-04-12 → 2026-07-31 |